Want to see TSE:VPT full AI Analyst Report?
VentriPoint Diagnostics (VPT) AI Stock Analysis
VentriPoint Diagnostics
(TSXV:VPT)
The score is driven primarily by severely distressed financial conditions, including negative equity, leverage, ongoing losses, and cash burn. Bearish technical positioning and the lack of valuation support further limit the score, despite revenue growth, strong gross margins, and moderating cash losses.
VentriPoint Diagnostics (VPT) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 15.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 128.56K
- Price to Earnings (P/E)
- -6.1
- Beta (1Y)
- -0.76
- Revenue Growth
- 89.06%
- EPS Growth
- 37.62%
- Country
- Canada
- Employees
- 10
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
VentriPoint Diagnostics Business Overview & Revenue Model
Company Description
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of th...
VentriPoint Diagnostics Financial Statement Overview
Summary
Financial performance is severely weak: persistent operating and net losses, deeply negative equity, rising debt relative to company size, shrinking assets, and consistently negative operating cash flow outweigh revenue growth and strong gross margins.
Income Statement
34NegativeBalance Sheet
9Very NegativeCash Flow
21Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.77K | 179.93K | 95.17K | 49.18K | 68.17K | 0 |
| Gross Profit | 132.34K | 118.69K | 95.17K | 42.43K | 57.81K | -48.81K |
| EBITDA | -1.66M | -2.67M | -4.76M | -4.74M | -4.79M | -3.81M |
| Net Income | -2.32M | -3.20M | -4.92M | -4.87M | -4.87M | -3.88M |
Balance Sheet | ||||||
| Total Assets | 611.88K | 472.08K | 658.02K | 1.88M | 5.98M | 9.54M |
| Cash, Cash Equivalents and Short-Term Investments | 333.63K | 55.39K | 60.55K | 1.29M | 5.19M | 9.27M |
| Total Debt | 2.62M | 2.60M | 1.63M | 412.44K | 459.08K | 159.97K |
| Total Liabilities | 4.44M | 4.59M | 3.64M | 1.69M | 1.42M | 1.21M |
| Stockholders Equity | -3.83M | -4.12M | -2.98M | 189.71K | 4.55M | 8.33M |
Cash Flow | ||||||
| Free Cash Flow | -1.92M | -1.55M | -3.39M | -3.80M | -4.14M | -3.15M |
| Operating Cash Flow | -1.92M | -1.55M | -3.39M | -3.80M | -4.14M | -3.15M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -4,257 |
| Financing Cash Flow | 2.02M | 1.53M | 2.20M | -102.36K | 87.65K | 11.89M |
VentriPoint Diagnostics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VPT, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VPT.
VentriPoint Diagnostics Peers Comparison
Overall Rating
TSE:PRN50Neutral
TSE:TLT41.2Neutral- TSE:VPT39Underperform
TSE:PINK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:PRN | 50Neutral | CAD 335.37M | -6.79 | -62.45% | ― | 59.60% | 32.53% |
| TSE:TLT | 41Neutral | CAD 55.89M | -12.68 | -130.04% | ― | -24.86% | 18.29% |
| TSE:VPT | 39Underperform | CAD 15.43M | -6.13 | 56.40% | ― | 89.06% | 37.62% |
| TSE:PINK | 38Underperform | CAD 27.62M | -1.41 | -303.05% | ― | 35.27% | 58.34% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:VPT | VentriPoint Diagnostics | 0.08 | -0.02 | -20.00% | |
| TSE:PINK | Perimeter Medical Imaging Ai Inc | 0.18 | -0.05 | -23.40% | |
| TSE:PRN | Profound Medical | 9.18 | 0.91 | 11.00% | |
| TSE:TLT | Theralase Technologies | 0.18 | -0.02 | -10.00% |
VentriPoint Diagnostics Corporate Events
Ventripoint Steps Up Global Push for AI Cardiac Platform and Plans Shareholder Update
PositiveVentripoint Diagnostics is advancing commercialization of its VMS+ cardiac imaging platform, reporting a new system sale to a U.S. Midwest children’s hospital, expanded lead generation via its CRM, and increased customer engagement through virt...
Ventripoint Clears Key Global Quality Audits as VMS+ Commercialization Advances
PositiveVentripoint Diagnostics has successfully completed its annual quality and regulatory audits under the Medical Device Single Audit Program, ISO 13485:2016 and the EU Medical Device Regulation, confirming that its quality management system continues to...
Ventripoint Raises Capital and Adds Advisors to Drive VMS+ Commercialization
PositiveVentripoint Diagnostics has closed the first tranche of a non-brokered private placement, raising $180,000 toward a planned $350,000 financing to support commercialization of its VMS+™ cardiac imaging platform. The capital will be directed to s...
Ventripoint and UniDoc Explore Remote AI Cardiac Imaging Collaboration
PositiveVentripoint Diagnostics has signed a memorandum of understanding with UniDoc Health to evaluate integrating its AI-enabled VMS+ cardiac imaging platform into UniDoc’s connected-care infrastructure. The collaboration would pair UniDoc’s co...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026